Biocon Biologics and Civica Inc: Expanding Access to Diabetes Medication in the US
On a mission to make insulin more accessible and affordable, Biocon Biologics has entered into a strategic agreement with Civica, Inc., a not-for-profit organization. This partnership primarily focuses on improving the availability of Insulin Aspart in the United States.
Under this new collaboration, Biocon Biologics will be responsible for supplying the Insulin Aspart drug substance. Civica, Inc. will then utilize this substance to manufacture the finished Insulin Aspart drug product, a rapid-acting insulin analog, at its facility located in Petersburg, Virginia.
Civica plans to commercialize this essential medication following the successful completion of necessary development work and clinical trials. The agreement between the two organizations does not include any technology transfer, keeping the focus on production and distribution.
Biocon Biologics operates as a subsidiary of Biocon Ltd. The company stands out as a fully integrated global biologics entity, with capabilities that uniquely position it for commercial success through customized strategies aimed at creating lasting value for stakeholders.
Shreehas Tambe, the CEO and Managing Director of Biocon Biologics, expressed enthusiasm about the collaboration, highlighting it as a testament to their commitment to stakeholder value and patient needs.
Ned McCoy, President and CEO of Civica, Inc., recognized the partnership’s potential to advance Civica’s mission of providing vital medication access. “Utilizing our US-based manufacturing operations, we aim to produce prefilled pens and vials of insulin,” he stated, emphasizing the strategic use of domestic resources.
This collaboration with Civica comes in addition to an existing initiative by Biocon Biologics. The company’s own Insulin Aspart product is currently under review by the US Food and Drug Administration (FDA), which highlights its proactive pursuit of delivering crucial diabetes treatments to the US market.
In the United States alone, there are approximately 38.4 million people living with diabetes, which constitutes around 11.6% of the overall population. Alarmingly, a quarter of these cases remain undiagnosed. An additional 97.6 million Americans have been identified as having prediabetes, underscoring the urgent need for accessible treatment options.
The alliance between Biocon Biologics and Civica aims to directly tackle these challenges, expanding the availability of life-saving insulin to a wider US patient base.
The partnership signifies a step forward in addressing the pressing healthcare issue posed by diabetes, as well as a dedicated effort to bridge the treatment accessibility gap in the United States. As these organizations work collaboratively, the potential impacts on patient lives and the healthcare system could be profound, offering hope to millions in need of effective diabetes management solutions.
